ZAI LAB-Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?

Group 1 - Zai Lab Limited's shares increased by 14.7% to close at $33.18, with a significant trading volume compared to normal sessions, and a total gain of 42.3% over the past four weeks [1][2] - The stock price surge followed the announcement of a 74% objective response rate for ZL-1310 in a global phase Ia/Ib study for recurrent extensive-stage small cell lung cancer (SCLC), indicating strong potential for the investigational candidate [2] - Zai Lab plans to further evaluate ZL-1310 both as a single agent and in combination therapies for extensive-stage SCLC, following positive early-stage study results showing that the candidate was generally safe and well-tolerated [2] Group 2 - The company is expected to report a quarterly loss of$ 0.74 per share, reflecting a year-over-year decrease of 4.2%, while revenues are projected to be $103.54 million, representing a 49.6% increase from the previous year [2] - The consensus EPS estimate for Zai Lab has been revised 3.7% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not correlate with price appreciation [3] - Zai Lab is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Adma Biologics, has also been noted with a Zacks Rank of 3 (Hold) [3][4]